Should we use apoB for risk assessment and as a target for treatment?
Emory University School of Medicine, 1670 Clairmont Road, Atlanta, GA 30033, USA. editorjcl@yahoo.com
W Virgil
WV
Brown
Gary L
GL
Myers
Allan D
AD
Sniderman
Evan
E
Stein
D000890:Anti-Infective Agents / Q000627:therapeutic use; D001055:Apolipoproteins B / Q000097:blood* / Q000592:standards; D050197:Atherosclerosis / Q000097:blood* / Q000188:drug therapy / Q000209:etiology*; D015415:Biomarkers / Q000097:blood; D001774:Blood Chemical Analysis / Q000592:standards; D008078:Cholesterol, LDL / Q000097:blood; D002986:Clinical Trials as Topic; D006801:Humans; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D012307:Risk Factors
D000890:Anti-Infective Agents; D001055:Apolipoproteins B; D015415:Biomarkers; D008078:Cholesterol, LDL; D008055:Lipids; D008074:Lipoproteins